
News|Articles|February 3, 2025
Data-Driven Insights can Optimize Clinical Trial Site Selection
Author(s)PurpleLab
Clinical trials are crucial for drug development but often face delays due to poor site selection, which can lead to protocol violations, poor data quality, and increased costs. Ninety percent of clinical trials fail to meet their timelines, and issues like inadequate staffing and patient recruitment are significant challenges. Traditional site selection methods are inefficient, and the COVID-19 pandemic has further complicated the process. Data-driven insights can optimize site selection by evaluating current data on patient populations, investigators, and site capabilities.
Trending on Applied Clinical Trials Online
1
What Needs to Be True Across Sponsors, Sites, and Regulators for Operation TrialBlazer to Succeed
2
ACT Brief: Trial Failures as Administrative Problems, CRO Consolidation for Global Trial Reach, and FDA Approval of First FOP Treatment
3
Curavit Acquires Lindus Health Clinical Research Organization Assets to Expand US and European Trial Operations
4
When the Slack Runs Out: AI and the CRO Operating Model
5